

VERB kit fulfils your research needs: capture of intact SARS-CoV-2 viral particles, detection of neutralizing antibodies and beyond

- Covirabio's VERB kit enables rapid capture of intact SARS-CoV-2 (all variants) from a variety of sample matrices, using ACE2 functionalized magnetic beads
- The VERB kit also enables the determination of neutralizing antibody titer to study the status of the immune responses in a BSL2 lab environment
- This innovation using new ACE2-functionalized magnetic beads will strengthen the VERB platform's leading role in intact viral particle capture and neutralizing antibody detection, helping to further research to combat the COVID pandemic

Vienna, Austria, October 10th 2022 - Covirabio, an innovative biotech company, announced the launch of the VERB kit of its Virus Entry Receptor Binding (VERB) Platform for studies on SARS-CoV-2 research. The new ACE2 functionalized magnetic beads enable researchers to add capabilities in isolating all SARS-CoV-2 variants from a wide range of samples, as well as enabling research based on ACE2 binding ranging from neutralizing antibody detection, viral entry inhibitor screening, to spike protein purification.

The highly efficient binding of SARS-CoV-2 via its spike protein to its cellular entry receptor ACE2 - which is the basis for the successful initiation of the infection cycle of this virus - forms the molecular principle of the VERB Platform developed by Covirabio. A capture matrix has been developed which selectively binds infectious virus particles via ACE2 immobilized on a solid-phase matrix (magnetic bead). Specifically captured intact SARS-CoV-2 particles can be subsequently detected by conventional methods such as RT-qPCR or virus antigen tests and thus the detection can be integrated into existing processes by implementing a simple virus capture step into existing protocols.

The VERB kit makes use of the easy and efficient collection of beads in magnetic field to facilitate SARS-CoV-2 research in a simple workflow of "bind-wash-elute", which enables to first conduct feasibility studies in manual mode, and then run high-throughput studies in automatic mode.

For order information, quote, and technical support, please contact our dedicated team for Technical Customer Service (info@covirabio.com).

About Covirabio

Founded in 2020, Covirabio is a young and dynamic biotech company based in Vienna, Austria aiming to revolutionize infectious disease diagnosis.

Covirabio Contact Details

Dr Lei Pei
Product owner
lei.pei@covirabio.com

Disclaimer

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current knowledge and expectations, of which Covirabio can give no assurance. The actual results may differ materially in the future from the forward-looking statements including this new release due to various factors.